13.5 C
Imphal
Sunday, November 27, 2022
No menu items!

Dr Reddy Labs launches Lenalidomide Capsules in US

"Bringing a more affordable generic version to market creates greater patient access for this important drug.'

Must Read

Mumbai: Dr. Reddy’s Labs on Thursday announced the launch of Lenalidomide Capsules in the US market, a therapeutic equivalent generic version of REVLIMID (lenalidomide) Capsules approved by U. S. Food and Drug Administration (USFDA).

With this volume-limited launch, Dr. Reddy’s is eligible for first-to-market, 180 days of generic drug exclusivity for Lenalidomide Capsules in 2.5 mg and 20 mg strengths.

- Advertisement -

‘We are pleased with the first-to-market launch of two of our six strengths of Lenalidomide Capsules with 180-day market exclusivity,” says Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.

“Bringing a more affordable generic version to market creates greater patient access for this important drug.’

Dr. Reddy’s Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg, and 25 mg strengths, each in a bottle-count size of 21.

- Advertisement -
- Advertisement -

Latest News

Masterclasses, In-conversations add value to 53rd IFFI at Goa

Panaji: Learning being a continuous process, hundreds of delegates at the 53rd International Film Festival of India (IFFI) starting...
- Advertisement -

More Articles Like This

- Advertisement -